Abstract Details

Title Incidence and Clinical Characteristics of Parkinson’s Disease Psychosis in a Population-based Incidence Cohort in Olmsted County, MN (2006-2015).

Topic Neuroepidemiology

Presentation(s) S12 - Neuroepidemiology (2:24 PM-2:36 PM)

Poster/Presentation
Number 008

Background

Psychosis is a common symptom of Parkinson's Disease (PD) and may affect patients’ quality of life. However, few studies have investigated the incidence of psychosis in PD within a population-based cohort.

Objective To define the incidence, clinical features, and medications used in a cohort of patients with Parkinson’s Disease Psychosis (PDP).

Design/Methods The Rochester Epidemiology Project was used to define a population-based incident cohort of PD from 2006-2015 in Olmsted County, MN. A movement disorder specialist reviewed all clinical charts to confirm the diagnosis of PD. PDP was diagnosed using the NINDS/NIMH unified criteria.

Results

In the cohort of 225 PD patients, 69 (31%) cases met diagnostic criteria for PDP. PDP incidence among PD patients was 3.51/100 person-years and the median age of onset of psychosis was 79.8 years (IQR: 74.7-85.8). Visual hallucinations were the most frequent psychotic feature (72.5%), followed by delusions (26.1%). Psychosis was transient in 44/69 (63.8%) of the PDP cases, with a median duration of 68 days (IQR: 29.5-388). Overall, 45% (31/69) of PDP patients were prescribed an antipsychotic medication. In PDP patients, a similar percent of those with transient psychosis were prescribed antipsychotic medications 20/44 (45%) as those with persistent psychosis 11/25 (42%). This difference was not statistically significant (p= 0.80). Antipsychotic medications included quetiapine (28.6%), olanzapine (4.3%), and haloperidol (4.3%), with a median treatment time of 2.8 years (IQR: 0.3-4.0).

Conclusions The incidence of psychosis in our PD cohort was 3.51 cases per 100 person-years. Visual hallucinations and delusions were the most frequently observed psychotic features.
Psychosis symptoms were resolved in almost 2/3 of PDP cases within two months from onset. Overall, 45% of PDP cases were prescribed an antipsychotic medication. The percentage of PDP patients prescribed an antipsychotic was similar between those with transient and persistent psychosis.

Authors/Disclosures
Emanuele Camerucci, MD (Kansas University Medical Center) PRESENTER	Dr. Camerucci has nothing to disclose.
Aidan Mullan (Mayo Clinic)	No disclosure on file
	No disclosure on file
Pierpaolo Turcano, MD (Mayo Clinic)	Dr. Turcano has nothing to disclose.
Cole D. Stang	Mr. Stang has nothing to disclose.
James H. Bower, MD, MSc, FAAN (Mayo Clinic)	The institution of Dr. Bower has received research support from Abbvie.
Bradley F. Boeve, MD, FAAN (Mayo Clinic)	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.